Werewolf Therapeutics, Inc. HOWL
Set alert
At close
Pre-market · Nov 3, 7:18 AM ET
- YTD
- +65.62%
- 1 year
- -19.85%
- Open
- 0.9862
- Prev close
- 0.9861
- Mkt cap
- 51.03M
- Vol
- 272.20K
- Avg vol
- 6.69M
- EPS
- -0.73
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.9862
- High
- 1.06
- Forward P/E
- -0.86
- Beta
- 0.41
- Short ratio
- 2.09
- Inst. own
- 72.62%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 8, 2024
- 50-d avg
- 2.11
- 200-d avg
- 3.31
- 1y target
- 12.00
3M chart
Signals (14)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | Oct 30, 2026 | 3 days ago |
| MACD: Buy Signal | Oct 29, 2026 | 4 days ago |
| MACD: Sell Signal | Oct 23, 2026 | 1 week ago |
| MACD: Buy Signal | Oct 19, 2026 | 2 weeks ago |
| SMA: Bullish | Oct 9, 2026 | 3 weeks ago |
| SMA: Bearish | Oct 1, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 11, 2026 | 1 month ago |
| RSI: Overbought | Aug 21, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 18, 2026 | 2 months ago |
| SMA: Bullish | Aug 13, 2026 | 2 months ago |
| SMA: Bearish | Aug 12, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 10, 2026 | 2 months ago |
| SMA: Bullish | Aug 4, 2026 | 3 months ago |
| SMA: Bullish | Aug 4, 2026 | 3 months ago |
Key statistics
- Market cap
- 69.96M
- Enterprise value
- -15.19M
- Trailing P/E
- 0.00
- Forward P/E
- -0.86
- PEG ratio
- 0.00
- Price / sales
- 20.66
- Price / book
- 0.77
- EPS (TTM)
- -1.52
- Beta
- 0.41
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 3.39M
- Revenue growth
- 0.00%
- Free cash flow
- -27.67M
- Total cash
- 122.83M
- Total debt
- 36.78M
- Return on equity
- -61.56%
- Shares outstanding
- 44.56M
- Short % of float
- 4.67%
- 50-day average
- 2.11
- 200-day average
- 3.31
Analyst view
Consensus: none
- Target (low)
- 8.00
- Target (mean)
- 12.00
- Target (high)
- 15.00
- Strong buy2
- Buy4
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 8, 2024
Expected Aug 8, 2024. Consensus EPS estimate -0.275.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.41 | -0.38 | +0.03 | +7.32% |
| Aug 8, 2024 | Jun 1, 2024 | -0.38 | -0.43 | -0.05 | -13.16% |
| Aug 8, 2024 | Jun 1, 2024 | -0.38 | — | — | — |
| May 3, 2024 | Mar 1, 2024 | -0.35 | -0.39 | -0.04 | -11.43% |
| May 3, 2024 | Mar 1, 2024 | -0.35 | — | — | — |
| Mar 7, 2024 | Dec 1, 2023 | -0.43 | -0.33 | +0.10 | +23.26% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 19, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jul 2, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 26, 2024 | JMP Securities | reit | Market Outperform | Market Outperform |
| Jun 26, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 4, 2024 | JMP Securities | reit | Market Outperform | Market Outperform |
| Jun 3, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Werewolf Therapeutics, Inc.
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- werewolftx.com
News
- Werewolf Therapeutics To Present Two Posters On WTX-124, WTX-330 Data At Upcoming SITC 2026 Annual Meeting
- Werewolf Therapeutics Selected for Oral Presentation and to Present Posters at the Society for Immunotherapy of Cancer's (SITC) 2026 Annual Meeting
- 12 Health Care Stocks Moving In Tuesday's After-Market Session
- 12 Health Care Stocks Moving In Friday's Intraday Session
- Gold Moves Higher; US Composite PMI Surges In August
- Dow Jumps 350 Points; BJ's Wholesale Club Posts Upbeat Earnings
- Werewolf Therapeutics Takes Aim At Untapped Pain Market With Ambros Deal
- One of Israel Englander's Biotech Picks Just Turned Into a $500M Merger Story
- 12 Health Care Stocks Moving In Friday's Pre-Market Session
- Why Ross Stores Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
Your note
Sign in to keep a note on HOWL — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Jan 5, 2023 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| RA Capital Management, L.P. | 13.79% | 6,144,881 | 9.65M | Sep 29, 2024 |
| MPM Asset Management, LLC | 9.61% | 4,284,172 | 6.73M | Sep 29, 2024 |
| Pfm Health Sciences, Lp | 7.63% | 3,398,747 | 5.34M | Sep 29, 2024 |
| MPM BioImpact Capital LLC | 5.36% | 2,388,011 | 3.75M | Sep 29, 2024 |
| Bank of America Corporation | 4.83% | 2,153,717 | 3.38M | Sep 29, 2024 |
| Adage Capital Partners GP L.L.C. | 4.49% | 2,000,594 | 3.14M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.80% | 800,282 | 1.26M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 1.52% | 676,891 | 1.06M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.88% | 392,161 | 615.69K | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.70% | 310,654 | 487.73K | Aug 30, 2024 |
| iShares Russell 2000 Value ETF | 0.48% | 211,769 | 332.48K | Oct 30, 2024 |
| Fidelity Extended Market Index Fund | 0.38% | 171,305 | 268.95K | Oct 30, 2024 |